产品
编 号：F152006
分子式：C17H20N4O2
分子量：312.37
分子式：C17H20N4O2
分子量：312.37
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 140405-36-3
产品详情
生物活性：
RSVA405 is a potent, orally active activator of AMPK, with an EC50 of 1 μM. RSVA405 facilitates CaMKKβ-dependent activation of AMPK, inhibits mTOR, and promotes autophagy to increase Aβ degradation. RSVA405 has anti-inflammatory effects through the inhibition of STAT3 function. RSVA405 can also be used for the research of obesity.
体内研究：
RSVA405 (3 mg/kg; i.p.) attenuates renal injury and protects renal function after ischemia-reperfusion (I/R) in rats.RSVA405 (20-100 mg/kg/d; p.o. for 11 weeks) significantly reduces the body weight gain of mice fed a high-fat diet.Animal Model:Male Sprague-Dawley rats (300-350 g) are induced I/R injury
Dosage:3 mg/kg
Administration:I.p. one hour before inducing I/R injury
Result:Decreased the levels of creatinine and blood urea nitrogen (BUN), by 35.8% and 44.3% in serum, respectively.Decreased the levels of aspartate aminotransferase (AST) and lactate dehydrogenase (LDH) by 33.0% and 59.8% in serum, respectively.
体外研究：
RSVA405 (0.2-2 μM; 24 h) inhibits adipocyte differentiation.RSVA405 (0.2-2 μM; 24 h) significantly inhibits the expression of peroxisome proliferator-activated receptor (PPAR)-γ, fatty acid synthase (FAS) and fatty acid binding protein 4 (aP2) in 3T3-L1 cells.RSVA405 (1-3 μM; 16 h) inhibits LPS-induced STAT3 activity, intracellular signaling, and cytokine response in activated RAW 264.7 macrophages.RSVA405 (1-3 μM; 24 h) inhibits mTOR, induces autophagy, and facilitates the lysosomal degradation of Aβ, with an EC50 of ～1 μM in APP-HEK293 cells.
RSVA405 is a potent, orally active activator of AMPK, with an EC50 of 1 μM. RSVA405 facilitates CaMKKβ-dependent activation of AMPK, inhibits mTOR, and promotes autophagy to increase Aβ degradation. RSVA405 has anti-inflammatory effects through the inhibition of STAT3 function. RSVA405 can also be used for the research of obesity.
体内研究：
RSVA405 (3 mg/kg; i.p.) attenuates renal injury and protects renal function after ischemia-reperfusion (I/R) in rats.RSVA405 (20-100 mg/kg/d; p.o. for 11 weeks) significantly reduces the body weight gain of mice fed a high-fat diet.Animal Model:Male Sprague-Dawley rats (300-350 g) are induced I/R injury
Dosage:3 mg/kg
Administration:I.p. one hour before inducing I/R injury
Result:Decreased the levels of creatinine and blood urea nitrogen (BUN), by 35.8% and 44.3% in serum, respectively.Decreased the levels of aspartate aminotransferase (AST) and lactate dehydrogenase (LDH) by 33.0% and 59.8% in serum, respectively.
体外研究：
RSVA405 (0.2-2 μM; 24 h) inhibits adipocyte differentiation.RSVA405 (0.2-2 μM; 24 h) significantly inhibits the expression of peroxisome proliferator-activated receptor (PPAR)-γ, fatty acid synthase (FAS) and fatty acid binding protein 4 (aP2) in 3T3-L1 cells.RSVA405 (1-3 μM; 16 h) inhibits LPS-induced STAT3 activity, intracellular signaling, and cytokine response in activated RAW 264.7 macrophages.RSVA405 (1-3 μM; 24 h) inhibits mTOR, induces autophagy, and facilitates the lysosomal degradation of Aβ, with an EC50 of ～1 μM in APP-HEK293 cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备